Candel Therapeutics To Present Data From Its Phase 2 Clinical Trial Of CAN-2409 At ASCO
Candel Therapeutics To Present Data From Its Phase 2 Clinical Trial Of CAN-2409 At ASCO
Candel Therapeutics 將在 ASCO 公佈其 CAN-2409 二期臨床試驗的數據
As of the data cut-off date, CAN-2409 treatment in NSCLC continued to exhibit a favorable safety and tolerability profile
截至數據截止日期，NSCLC 的 CAN-2409 治療繼續表現出良好的安全性和耐受性
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。